Effects of acetyl-DL-leucine on cerebellar ataxia (ALCAT trial): study protocol for a multicenter, multinational, randomized, double-blind, placebo-controlled, crossover phase III trial.

MLA

Feil, Katharina, et al. “Effects of Acetyl-DL-Leucine on Cerebellar Ataxia (ALCAT Trial): Study Protocol for a Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Crossover Phase III Trial.” BMC Neurology, vol. 17, Jan. 2017, pp. 1–11. EBSCOhost, https://doi.org/10.1186/s12883-016-0786-x.

APA

Feil, K., Adrion, C., Teufel, J., Bösch, S., Claassen, J., Giordano, I., Hengel, H., Jacobi, H., Klockgether, T., Klopstock, T., Nachbauer, W., Schöls, L., Stendel, C., Uslar, E., van de Warrenburg, B., Berger, I., Naumann, I., Bayer, O., Müller, H.-H., & Mansmann, U. (2017). Effects of acetyl-DL-leucine on cerebellar ataxia (ALCAT trial): study protocol for a multicenter, multinational, randomized, double-blind, placebo-controlled, crossover phase III trial. BMC Neurology, 17, 1–11. https://doi.org/10.1186/s12883-016-0786-x

Chicago

Feil, Katharina, Christine Adrion, Julian Teufel, Sylvia Bösch, Jens Claassen, Ilaria Giordano, Holger Hengel, et al. 2017. “Effects of Acetyl-DL-Leucine on Cerebellar Ataxia (ALCAT Trial): Study Protocol for a Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Crossover Phase III Trial.” BMC Neurology 17 (January): 1–11. doi:10.1186/s12883-016-0786-x.